Atlas Trials

A Study of Herceptin (Trastuzumab) in Combination With Xeloda (Capecitabine) in Patients With Metastatic or Recurrent HER2-positive Breast Cancer After First-Line or (Neo)Adjuvant Therapy.

Clinical trial NCT01290718 · TERMINATED

Trial details

NCT number
NCT01290718
Sponsor
Hoffmann-La Roche
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2011-12-01
Primary completion
2012-12-01
Enrollment
4

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.